Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial
We aimed to assess the safety and efficacy of galcanezumab, an antibody to calcitonin gene-related peptide. The primary endpoint was the overall mean change from baseline in a number of monthly migraine headache days during the 3-month treatment period.
